JP2025503052A - ユビキチン特異的プロテアーゼ７阻害剤としてのヘテロ環式化合物 - Google Patents
ユビキチン特異的プロテアーゼ７阻害剤としてのヘテロ環式化合物 Download PDFInfo
- Publication number
- JP2025503052A JP2025503052A JP2024543181A JP2024543181A JP2025503052A JP 2025503052 A JP2025503052 A JP 2025503052A JP 2024543181 A JP2024543181 A JP 2024543181A JP 2024543181 A JP2024543181 A JP 2024543181A JP 2025503052 A JP2025503052 A JP 2025503052A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- chloro
- phenyl
- pyrrolo
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2200753.8A GB202200753D0 (en) | 2022-01-21 | 2022-01-21 | Pharmaceutical compounds |
| GB2200753.8 | 2022-01-21 | ||
| PCT/EP2023/051447 WO2023139241A1 (en) | 2022-01-21 | 2023-01-20 | Heterocyclic compounds as ubiquitin specific protease 7 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503052A true JP2025503052A (ja) | 2025-01-30 |
| JP2025503052A5 JP2025503052A5 (https=) | 2026-01-05 |
Family
ID=80507367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543181A Pending JP2025503052A (ja) | 2022-01-21 | 2023-01-20 | ユビキチン特異的プロテアーゼ７阻害剤としてのヘテロ環式化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250122223A1 (https=) |
| EP (1) | EP4466072A1 (https=) |
| JP (1) | JP2025503052A (https=) |
| CN (1) | CN118946566A (https=) |
| GB (1) | GB202200753D0 (https=) |
| WO (1) | WO2023139241A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202001980D0 (en) * | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| US20240150362A1 (en) | 2022-08-25 | 2024-05-09 | Molecure S.A. | Substituted Pyrrolotriazines |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2200753B (en) | 1986-12-23 | 1991-01-23 | Brookes & Gatehouse | Speed measurement device |
| EP1749822B1 (en) | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| US7875613B2 (en) | 2006-10-30 | 2011-01-25 | Hybrigenics Sa | Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| EP2208725A1 (en) | 2009-01-13 | 2010-07-21 | Hybrigenics S.A. | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
| WO2010114881A1 (en) | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
| US20110177105A1 (en) | 2010-01-15 | 2011-07-21 | Roman Lopez | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| US9840491B2 (en) | 2015-02-05 | 2017-12-12 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| CN107531683B (zh) | 2015-03-20 | 2022-05-13 | 豪夫迈·罗氏有限公司 | Usp7抑制剂化合物及使用方法 |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
-
2022
- 2022-01-21 GB GBGB2200753.8A patent/GB202200753D0/en not_active Ceased
-
2023
- 2023-01-20 WO PCT/EP2023/051447 patent/WO2023139241A1/en not_active Ceased
- 2023-01-20 US US18/729,403 patent/US20250122223A1/en active Pending
- 2023-01-20 EP EP23701878.3A patent/EP4466072A1/en active Pending
- 2023-01-20 JP JP2024543181A patent/JP2025503052A/ja active Pending
- 2023-01-20 CN CN202380027580.0A patent/CN118946566A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250122223A1 (en) | 2025-04-17 |
| WO2023139241A1 (en) | 2023-07-27 |
| EP4466072A1 (en) | 2024-11-27 |
| GB202200753D0 (en) | 2022-03-09 |
| CN118946566A (zh) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4306529B1 (en) | Fgfr inhibitors and methods of use thereof | |
| US10766903B2 (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
| JP7665518B2 (ja) | 化合物及びその使用 | |
| CN111801327B (zh) | 苯甲酰胺化合物 | |
| TWI650319B (zh) | 用於調節表皮生長因子受體（ｅｇｆｒ）活性之化合物及組合物 | |
| JP2023518722A (ja) | Ｙａｐ／ｔａｚ－ｔｅａｄタンパク質－タンパク質相互作用阻害剤としてのビアリール誘導体 | |
| JP2023518145A (ja) | 化合物及びその使用 | |
| CA3118330A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| US12071425B2 (en) | Phenoxy-pyridyl-pyrimidine compounds and methods of use | |
| WO2023059609A1 (en) | Heterobifunctional compounds and their use in treating disease | |
| WO2016102493A1 (en) | Imidazopyridine ezh2 inhibitors | |
| JPWO2017111074A1 (ja) | ピロロピリミジン化合物による抗腫瘍効果増強剤 | |
| US10501466B2 (en) | WDR5 inhibitors and modulators | |
| JP2025503052A (ja) | ユビキチン特異的プロテアーゼ７阻害剤としてのヘテロ環式化合物 | |
| KR20230160901A (ko) | 유비퀴틴 특이 프로테아제 19(usp19)의 억제제로서의 약제학적 화합물 | |
| EP3672962A1 (en) | Morpholinylpyridone compounds | |
| JP6586463B2 (ja) | ＰＩ３Ｋβ阻害剤としての複素環連結イミダゾピリダジン誘導体 | |
| KR20220077140A (ko) | 프로스타글란딘 e2(pge2) ep4 수용체 길항제 | |
| WO2023209090A1 (en) | Bicyclic heteroaromatic compounds and their application in the treatment of cancer | |
| AU2023237749A1 (en) | Tead inhibitors and methods of use | |
| CN117597346A (zh) | Nek7抑制剂 | |
| RU2830596C1 (ru) | Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead | |
| WO2025146502A1 (en) | Coronavirus inhibiting compounds | |
| JP2025516584A (ja) | 化合物及びその使用 | |
| EA047452B1 (ru) | Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251219 |